Quick Answer
Rapport Therapeutics, Inc. reported Earnings Per Share Diluted of $2.86 (loss) per share for the year ending 2025.
- Rapport Therapeutics, Inc. showed an increase of +24.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Rapport Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 3 years of available data (2023 to 2025), Rapport Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 87.6%.
- Historical annual values: Fiscal year 2025: $2.86 (loss) per share | Fiscal year 2024: $3.78 (loss) per share | Fiscal year 2023: $23.10 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: